 CAMBRIDGE, Mass.--BUSINESS WIRE--InVivo Therapeutics Holdings Corp. Nasdaq: NVIV, a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75 of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial 20-patient, 10 subjects in each study arm, that is designed 